Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Hepacid (pegargiminase)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Polaris Pharma

Drug class:

Arginine depleter

ASS1 mutation	Malignant Pleural Mesothelioma	ASS1 mutation	Malignant Pleural Mesothelioma	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials cisplatin + pemetrexed + pegargiminase Sensitive : C3	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials cisplatin + pemetrexed + pegargiminase Sensitive : C3
ASS1 negative	Uveal Melanoma	ASS1 negative	Uveal Melanoma	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials cisplatin + pemetrexed + pegargiminase Sensitive : C3	cisplatin + pemetrexed + pegargiminase Sensitive: C3 – Early Trials cisplatin + pemetrexed + pegargiminase Sensitive : C3
ASS1 underexpression	Pancreatic Ductal Adenocarcinoma	ASS1 underexpression	Pancreatic Ductal Adenocarcinoma	panobinostat + pegargiminase Sensitive: D – Preclinical panobinostat + pegargiminase Sensitive : D	panobinostat + pegargiminase Sensitive: D – Preclinical panobinostat + pegargiminase Sensitive : D